Publication Date:
2020-09-07
Description:
Our objective was to validate the NSABP 8-gene trastuzumab-benefit signature, developed and initially validated in NRG Oncology/NSABP B-31 in Alliance/NCCTG N9831. The B-31 and N9831 trials demonstrated the benefit of adding trastuzumab to chemotherapy in the adjuvant setting for HER2+ breast cancer patients. NSABP investigators utilized gene expression profiles of N9831 patients (N = 892) to blindly assign patients to large-, moderate-, or no-trastuzumab benefit groups and then assessed the degree of trastuzumab benefit using Cox models adjusted for age, nodes, ER/PR status, tumor size, and grade. Hazard ratios and two-sided p values for recurrence-free survival of the predicted large- (n = 387), moderate- (n = 401), and no-benefit (n = 104) groups, based on the 8-gene signature were 0.47 (95%CI=0.31 to 0.73, P
Electronic ISSN:
2515-5091
Topics:
Chemistry and Pharmacology
,
Medicine
Permalink